Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Asset Writedowns and Impairment: 2021-2022

  • BridgeBio Pharma's Asset Writedowns and Impairment was N/A to $67,000 in Q3 2022 from the same period last year, while for Sep 2022 it was $12.7 million, marking a year-over-year change of. This contributed to the annual value of $271,000 for FY2024, which is N/A change from last year.
  • Per BridgeBio Pharma's latest filing, its Asset Writedowns and Impairment stood at $67,000 for Q3 2022, which was down 99.47% from $12.7 million recorded in Q1 2022.
  • BridgeBio Pharma's 5-year Asset Writedowns and Impairment high stood at $12.7 million for Q1 2022, and its period low was -$3.3 million during Q4 2021.
  • Its 2-year average for Asset Writedowns and Impairment is $3.2 million, with a median of $1.7 million in 2021.
  • Data for BridgeBio Pharma's Asset Writedowns and Impairment shows a peak YoY skyrocketed of 283.42% (in 2022) over the last 5 years.
  • Quarterly analysis of 2 years shows BridgeBio Pharma's Asset Writedowns and Impairment stood at -$3.3 million in 2021, then surged by 283.42% to $67,000 in 2022.
  • Its last three reported values are $67,000 in Q3 2022, $12.7 million for Q1 2022, and -$3.3 million during Q4 2021.